SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Small-Cap Stocks Battling Brain Cancer
EXEL
|
|
|
+8.80%
in
64 days
<font> Small-Cap Stocks Battling Brain Cancer <> Each year nearly 20,000 people in the U.S. are diagnosed with primary brain cancers (with a similar number in Europe), <font> according to NCI/NIH statistics </font> , with Schering-Plough's (NYSE:SGP) Temodar (temozolomide or TMZ is classified as a DNA-methylating chemotherapy drug) given to nearly every patient with a diagnosis of GBM (the most common and aggressive form of brain cancer). Newly diagnosed individuals with GBM typically undergo surgery (if possible) to remove the tumor, followed by radiation and chemother...
|
Top 40 Rated Emerging Bio-Pharma Stocks
EXEL
|
|
|
+20.42%
in
257 days
(closed on 09/06/09)
<> 
The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return.
The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP),...
|
Bullish on EXEL ...
EXEL
|
|
|
-8.37%
in
271 days
(closed on 01/30/07)
biotech company with a lot in the pipeline. Recommended by the Motley Fool, so I'm giving them a chance. I will start to begin looking into more biotech stocks in the near future - Baby boomers are getting older after all.
|
From the Blogosphere
Analyst upgrades, downgrades and initiations: WDC, NSTX, UBS, TIF, BA ...
Top 40 Rated Emerging Bio-Pharma Stocks
|
|
|
The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return.
The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP), and the Healthcare Sector SPDR (XLV) over the past year. Since I last updated ...
|
Top 40 Rated Emerging Bio-Pharma Stocks
|
|
|
The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return.
The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP), and the Healthcare Sector SPDR (XLV) over the past year. Since I last updated ...
|
Biotech Stock to watch: Exelixis, Inc (EXEL)
This company Exelixis is colloborating with BMY on a cancer drug that's getting  positive FDA data, here is the press release:
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today announced that Bristol-Myers Squibb Company (NYSE:BMY) has exercised its option to develop and commercialize Exelixis' investigational new drug (IND) candidate XL413, a selective inhibitor of Cdc7.
read more
|
Exelixis, Inc. (EXEL) CFO Sends Update on Company???s Progress
|
|
|
During the William Blair 28th Annual Growth Stock Conference in Chicago, the CFO of Exelixis, Inc. (EXEL) Frank Karbe, presented Thursday on the company’s corporate relationships with biotechnology and pharmaceutical companies, recent company funding, and other company news. Exelixis, Inc. is a developmental stage biotechnology company that has dedicated their efforts to the discovery and development of small molecule therapeutics for the treatment of cancer and other serious diseases. <>Mr. Karbe explained how Exelixis established important relationships with major pharmaceutical compani...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on EXEL |
Visit streetinsider.com
More Resources
|
About Exelixis Inc
- Answers.com
